Search Results

You are looking at 171 - 180 of 502 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Muhammed Aasim Yusuf, Vinay Kumar Kapoor, Refaat Refaat Kamel, Ather Kazmi, Najam Uddin, Nehal Masood, and Abdulmajeed Al-Abdulkareem

recommended removing the chemotherapy option because they believed the benefit of adjuvant chemotherapy remains unproven, and the only randomized trial examining this did not show any benefit in treating cholangiocarcinoma. 16 The committee also recommended

Full access

Axel Grothey and Alan P. Venook

Hematology and Medical Oncology, Mayo Clinic Cancer Center, who described this study at the NCCN 23rd Annual Conference. “I believe we have the first important changes in adjuvant chemotherapy since 2004,” Dr. Grothey said, referring to the adoption of 6

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars

-positive, T1 breast cancer (category 1 with tamoxifen; category 2A with an aromatase inhibitor). If adjuvant chemotherapy is indicated after breast-conserving surgery, radiation should be given after chemotherapy is completed. 73 , 74 This recommendation is

Full access

Nora M. Hansen, Sally Anne Scherer, and Seema Khan

but refused by the patient. The ASCO3 measure recommends that patients younger than 70 years with stage III (T1cN0), stage II, and stage I breast cancer receive adjuvant chemotherapy begun within 120 days of diagnosis. Among the institution’s subset

Full access

Maurie Markman

methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy . Cancer Res 1980 ; 40 : 3665 – 3668 . 6 Durand RE . Flow cytometry studies of intracellular adriamycin in multicell spheroids

Full access

Sarah Asad, Carlos H. Barcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis G. Levine, Nancy U. Lin, Beverly Moy, Joyce Niland, Antonio C. Wolff, Michael J. Hassett, and Daniel G. Stover

also been shown that among patients for whom chemotherapy would be standard of care, non-Hispanic Black patients had a significantly lower likelihood of receiving adjuvant chemotherapy. 34 Furthermore, a previous analysis of NCCN data demonstrated that

Full access

Brigette A. Davis, Jenerius A. Aminawung, Maysa M. Abu-Khalaf, Suzanne B. Evans, Kevin Su, Rajni Mehta, Shi-Yi Wang, and Cary P. Gross

-related genes and 5 reference genes) to generate a recurrence score (RS). Studies have shown that the RS is both prognostic—it correlates with 10-year risk of distant recurrence—and predictive of the degree to which adjuvant chemotherapy will reduce the risk of

Full access

Angela M. Davies, Philip C. Mack, Primo N. Lara Jr., Derick H. Lau, Kathleen Danenberg, Paul H. Gumerlock, and David R. Gandara

advanced or metastatic NSCLC . J Clin Oncol 2003 ; 21 : 2658 – 2663 . 36 Mitsudomi T Yatabe Y Tada H . Lack of predictive value of p53, p27, Bcl2, HER2/neu, EGFR alterations for efficacy of postoperative adjuvant chemotherapy consisting of

Full access

Heather Hampel

. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis . Eur J Cancer 2009 ; 45 : 1890 – 1896 . 3. Jarvinen HJ Renkonen-Sinisalo L Aktan-Collan K . Ten

Full access

chemotherapy is preferred for these patients to aid resectability. If IORT is not available, additional 10-20 Gy external beam radiation and/or brachytherapy could be considered to a limited volume. The ending of “prior to adjuvant chemotherapy” removed